Fate Thera gains after FDA go-ahead to advance CAR-T therapy in clinical studies
Seeking Alpha ·
Fate Therapeutics ( FATE ) traded higher on Thursday after the company said that the U.S. FDA cleared its Investigational New Drug application for its CAR-T cell therapy FT839, paving the way for its clinical development. With the IND clearance, the San Diego, California-based
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
434 participants
Related News
- Travelers cut to 'in line' by Evercore ISI as valuation limits upside
- Tiny Ltd. jumps on report of takeover interest for Letterboxd
- Nasdaq Composite triggers first MACD crossover in six weeks
- Honeywell Aerospace rated new Neutral at J.P. Morgan as A&D supplier 'in transition'
- SK hynix hits Nasdaq at $171; CEO expects memory crunch to extend beyond 2030
- Investing.com’s stocks of the week